Achaogen (AKAO) received a Hold rating and a $3 price target from H.C. Wainwright analyst Ed Arce today. The company’s shares closed on Friday at $2.25, close to its 52-week low of $2.10.
Arce observed:
“916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.92 $1.92 Shares outstanding 46,120 2018 ZEMDRI – EU 35% $0.64 $1.83 Current share price $2.25 Discount rate 18.0% C-Scape – U.S.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 13.5% and a 40.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Achaogen has an analyst consensus of Hold, with a price target consensus of $4.40, which is a 95.6% upside from current levels. In a report issued on November 9, Mizuho Securities also downgraded the stock to Hold with a $3 price target.
.
See today’s analyst top recommended stocks >>
Based on Achaogen’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $41.79 million. In comparison, last year the company had a GAAP net loss of $29.91 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
